According to a new study, a non-psychotropic component of marijuana called Cannabidiol may enhance the healing process of bone fissures. The study also found that bones treated with marijuana were stronger and less likely to fracture again In the wake of moves to legalize marijuana for medicinal purposes across many states, researchers are now digging […]

by

A cannabis derivative could help children with epilepsy, according to a series of studies presented at the American Epilepsy Society’s 69th Annual Meeting in Philadelphia, PA. A cannabis derivative appears to help prevent seizures. Cannabidiol (CBD), a type of cannabinoid, has come into focus as a potential therapy for various conditions, including epilepsy. CBD is […]

by

Erythropoietin (EPO) support during radiation therapy had no impact on outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) and mild or moderate anemia, long-term results of a randomized trial showed. Locoregional failure, locoregional progression-free survival (PFS), and overall survival (OS) did not differ significantly between patients who received concomitant EPO and those who […]

by

March 14, 2016 Cannabidiol Therapy Reduces Seizure Frequency in Dravet Syndrome Investigators have announced positive results for the first phase 3 clinical trial of GW Pharmaceutical’s cannabidiol therapy Epidiolex in patients with Dravet syndrome. The unpublished results mark a milestone for Epidiolex, which has already received Orphan Drug Designation and Fast Track Designation from the […]

by

WASHINGTON, March 14 (UPI) — The marijuana-based drug Epidiolex significantly reduced seizures in children with Dravet syndrome in a phase 3 clinical trial, lending scientific credence to a treatment used for several years but mostly supported by anecdotal evidence. GW Pharmaceuticals, which developed the drug, announced the results of the first of four trials with […]

by

Biopharmaceutical company GW Pharmaceuticals announced Monday positive results of its Phase 3 pivotal study for cannabidiol (CBD) treatment, Epidiolex, for the treatment of severe forms of epilepsy. Epidiolex is a liquid formulation of CDB, which is the most abundant non-psychoactive cannabinoid in the marijuana plant. “The results of this Epidiolex pivotal trial are important and […]

by

Shares of Cannabis Sativa Inc (OTCMKTS:CBDS) exploded up the charts on the back of positive news from GW Pharmaceuticals plc (NASDAQ:GWPH). GWPH announced positive results in a Phase 3 clinical trial assessing Orphan Drug- and Fast Track-tagged Epidiolex (cannabidiol) for the treatment of Dravet syndrome, a rare and catastrophic form of childhood epilepsy for which there are no […]

by

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, […]

by

The FDA designates Zynerba Pharmaceuticals’ (ZYNE +2%) ZYN002 cannabidiol gel an Orphan Drug for the treatment of Fragile X syndrome, a genetic disorder characterized by learning disabilities and cognitive impairment. ZYN002 is designed to deliver a controlled dose of cannabidiol transdermally via a permeation-enhanced gel formulation. A Phase 2 study should commence by year end. […]

by

TYLER, TX — (Marketwired) — 02/24/16 — Wisdom Homes of America, Inc. (the “Company”) (OTC PINK: WOFA) concentrates on licensing products and technology benefiting the cannabis patient and consumers. The Company is proud to announce that it has contracted with Healthy Asylum, Inc., a manufacturer of oral strips including CannaStrips. Healthy Asylum has completed an […]

by

PHILADELPHIA — In the largest study of its kind, researchers report that Epidiolex, a pharmaceutical-grade, purified form of cannabidiol, is generally well-tolerated and is a promising treatment for treatment-resistant epilepsies. The results, from the open-label Expanded Access treatment programs from 16 sites, were presented at the 2015 American Epilepsy Society Annual Meeting in Philadelphia. Epidiolex, […]

by